FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009598346> ?p ?o ?g. }

• W2009598346 endingPage "e103109" @default.
• W2009598346 startingPage "e103109" @default.
• W2009598346 abstract "Despite its side-effects, docetaxel (DTX) remains a first-line treatment against castration resistant prostate cancer (CRPC). Therefore, strategies to increase its anti-tumor efficacy and decrease its side effects are critically needed. Targeting of the constitutive endoplasmic reticulum (ER) stress in cancer cells is being investigated as a chemosensitization approach. We hypothesized that the simultaneous induction of ER-stress and suppression of PI3K/AKT survival pathway will be a more effective approach. In a CRPC cell line, C4-2B, we observed significant (p<0.005) enhancement of DTX-induced cytotoxicity following coexposure to thapsigargin and an AKT-inhibitor. However, since these two agents are not clinically approved, we investigated whether a combination of nelfinavir (NFR) and curcumin (CUR), known to target both these metabolic pathways, can similarly increase DTX cytotoxicity in CRPC cells. Within 24 hrs post-exposure to physiologic concentrations of NFR (5 µM) and CUR (5 µM) a significantly (p<0.005) enhanced cytotoxicity was evident with low concentration of DTX (10 nM). This 3-drug combination rapidly increased apoptosis in aggressive C4-2B cells, but not in RWPE-1 cells or in primary prostate epithelial cells (PrEC). Comparative molecular studies revealed that this 3-drug combination caused a more pronounced suppression of phosphorylated-AKT and higher induction in phosphorylated-eIF2α in C4-2B cells, as compared to RWPE-1 cells. Acute exposure (3–9 hrs) to this 3-drug combination intensified ER-stress induced pro-apoptotic markers, i.e. ATF4, CHOP, and TRIB3. At much lower concentrations, chronic (3 wks) exposures to these three agents drastically reduced colony forming units (CFU) by C4-2B cells. In vivo studies using mice containing C4-2B tumor xenografts showed significant (p<0.05) enhancement of DTX’s (10 mg/kg) anti-tumor efficacy following coexposure to NFR (20 mg/kg) & CUR (100 mg/kg). Immunohistochemical (IHC) analyses of tumor sections indicated decreased Ki-67 staining and increased TUNEL intensity in mice exposed to the 3-drug combination. Therefore, subverting ER-stress towards apoptosis using adjuvant therapy with NFR and CUR can chemosensitize the CRPC cells to DTX therapy." @default.
• W2009598346 created "2016-06-24" @default.
• W2009598346 creator A5022836469 @default.
• W2009598346 creator A5047578995 @default.
• W2009598346 creator A5050086899 @default.
• W2009598346 creator A5053732197 @default.
• W2009598346 creator A5078580387 @default.
• W2009598346 creator A5079760975 @default.
• W2009598346 creator A5085642649 @default.
• W2009598346 date "2014-08-14" @default.
• W2009598346 modified "2023-10-17" @default.
• W2009598346 title "Subverting ER-Stress towards Apoptosis by Nelfinavir and Curcumin Coexposure Augments Docetaxel Efficacy in Castration Resistant Prostate Cancer Cells" @default.
• W2009598346 cites W1496974689 @default.
• W2009598346 cites W1566654704 @default.
• W2009598346 cites W1970833175 @default.
• W2009598346 cites W1979882854 @default.
• W2009598346 cites W1986508603 @default.
• W2009598346 cites W1991397922 @default.
• W2009598346 cites W1994138076 @default.
• W2009598346 cites W2005529246 @default.
• W2009598346 cites W2013559520 @default.
• W2009598346 cites W2018439279 @default.
• W2009598346 cites W2018704721 @default.
• W2009598346 cites W2034535492 @default.
• W2009598346 cites W2041581075 @default.
• W2009598346 cites W2048869392 @default.
• W2009598346 cites W2052034388 @default.
• W2009598346 cites W2053442171 @default.
• W2009598346 cites W2058236541 @default.
• W2009598346 cites W2060045688 @default.
• W2009598346 cites W2062941476 @default.
• W2009598346 cites W2066723507 @default.
• W2009598346 cites W2067107748 @default.
• W2009598346 cites W2071943997 @default.
• W2009598346 cites W2074471441 @default.
• W2009598346 cites W2077380927 @default.
• W2009598346 cites W2088303467 @default.
• W2009598346 cites W2095054695 @default.
• W2009598346 cites W2096439168 @default.
• W2009598346 cites W2101761370 @default.
• W2009598346 cites W2101954532 @default.
• W2009598346 cites W2110506701 @default.
• W2009598346 cites W2115364083 @default.
• W2009598346 cites W2117654000 @default.
• W2009598346 cites W2119970046 @default.
• W2009598346 cites W2122684363 @default.
• W2009598346 cites W2127695803 @default.
• W2009598346 cites W2128510092 @default.
• W2009598346 cites W2128541396 @default.
• W2009598346 cites W2129516869 @default.
• W2009598346 cites W2135465113 @default.
• W2009598346 cites W2136729555 @default.
• W2009598346 cites W2137631271 @default.
• W2009598346 cites W2139216034 @default.
• W2009598346 cites W2151015976 @default.
• W2009598346 cites W2151092952 @default.
• W2009598346 cites W2151262728 @default.
• W2009598346 cites W2152163817 @default.
• W2009598346 cites W2161908322 @default.
• W2009598346 cites W2166630192 @default.
• W2009598346 cites W2170967403 @default.
• W2009598346 cites W2277933729 @default.
• W2009598346 cites W4235151556 @default.
• W2009598346 doi "https://doi.org/10.1371/journal.pone.0103109" @default.
• W2009598346 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4133210" @default.
• W2009598346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25121735" @default.
• W2009598346 hasPublicationYear "2014" @default.
• W2009598346 type Work @default.
• W2009598346 sameAs 2009598346 @default.
• W2009598346 citedByCount "49" @default.
• W2009598346 countsByYear W20095983462015 @default.
• W2009598346 countsByYear W20095983462016 @default.
• W2009598346 countsByYear W20095983462017 @default.
• W2009598346 countsByYear W20095983462018 @default.
• W2009598346 countsByYear W20095983462019 @default.
• W2009598346 countsByYear W20095983462020 @default.
• W2009598346 countsByYear W20095983462021 @default.
• W2009598346 countsByYear W20095983462022 @default.
• W2009598346 countsByYear W20095983462023 @default.
• W2009598346 crossrefType "journal-article" @default.
• W2009598346 hasAuthorship W2009598346A5022836469 @default.
• W2009598346 hasAuthorship W2009598346A5047578995 @default.
• W2009598346 hasAuthorship W2009598346A5050086899 @default.
• W2009598346 hasAuthorship W2009598346A5053732197 @default.
• W2009598346 hasAuthorship W2009598346A5078580387 @default.
• W2009598346 hasAuthorship W2009598346A5079760975 @default.
• W2009598346 hasAuthorship W2009598346A5085642649 @default.
• W2009598346 hasBestOaLocation W20095983461 @default.
• W2009598346 hasConcept C109316439 @default.
• W2009598346 hasConcept C121608353 @default.
• W2009598346 hasConcept C126322002 @default.
• W2009598346 hasConcept C139447449 @default.
• W2009598346 hasConcept C185592680 @default.
• W2009598346 hasConcept C190283241 @default.
• W2009598346 hasConcept C202751555 @default.
• W2009598346 hasConcept C2778250585 @default.
• W2009598346 hasConcept C2780192828 @default.
• W2009598346 hasConcept C2781190966 @default.

• next